#USA #Amgen #Thousand Oaks #Repatha #cardiometabolic

Amgen Highlights Groundbreaking Cardiometabolic Data at ADA 86th Scientific Sessions

On June 7, 2026, Amgen (NASDAQ:AMGN) presented significant findings at the American Diabetes Association (ADA) 86th Scientific Sessions, underscoring its dedication to improving outcomes for those living with cardiometabolic issues. The company unveiled new Phase 3 results from the VESALIUS-CV trial, focused on its innovative treatment, Repatha® (evolocumab), which specifically targets high-risk diabetes patients amid escalating cardiovascular risks.

Concerning Diabetes and Cardiovascular Risk

Diabetes significantly heightens the risk of severe cardiovascular events, making effective management crucial. The VESALIUS-CV trial demonstrated that when Repatha was administered alongside statins or LDL-C-lowering therapies, it led to a 29% reduction in major cardiovascular events, including fatal coronary heart disease, heart attack, and ischemic stroke, compared to placebo. This pivotal data indicates the potential of Repatha in mitigating risks for those with high-risk diabetes, especially concerning LDL-C levels.

Key Trial Insights

The extensive study extended over a cohort of 6,002 patients, revealing a significant drop in median LDL-C levels from 106 mg/dL in placebo groups to 45 mg/dL in those treated with Repatha. Approximately a third of the participants were on SGLT2 inhibitors, while about 20% were administered GLP-1 receptor agonists, confirming that Repatha's effect on LDL-C management is consistent, independent of other ongoing treatments. This strengthens the reasoning behind multi-faceted risk management strategies in high-risk diabetic patients.

Dr. Jay Bradner, Amgen's executive vice president, pointed out the dire need for aggressive LDL-C reduction as a preventive strategy for those at high risk, emphasizing that early intervention can significantly alter outcomes for patients.

Addressing Treatment Gaps in Obesity and Diabetes Care

In addition to presenting data about Repatha, Amgen shed light on ongoing treatment gaps in obesity and diabetes care. Real-world evidence showcased that while GLP-1 therapies yield improvements in glycemic control and weight management, patient adherence remains disappointing. Many patients discontinue treatment within the first year, which could hinder the attainment of critical therapeutic goals.

New Approaches Needed

The discontinuation rates highlight a pressing need for innovative treatment methodologies and care strategies that can foster long-term adherence among patients. Such improvements are vital for allowing individuals to experience the full scope of benefits from existing therapies. Amgen's broader agenda aims to leverage its legacy of innovation in addressing the complex challenges posed by obesity and related comorbidities.

Significant Presentations at the ADA 2026

Key presentations made by Amgen at the ADA 2026 included:

• - Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Discussing the pivotal findings from the VESALIUS-CV trial from a meticulous perspective.
• - Lipid Management in High-Risk Diabetes: Sharing insights from the VESALIUS-REAL Global Study that emphasizes the relevance of effective lipid management strategies to mitigate cardiovascular event risks.
• - Real-World Impacts of GLP-1 Therapies: A meta-analysis addressing the adherence limits to glucagon-like peptide-1 treatments among type 2 diabetes patients.

Amgen's Commitment to Cardiometabolic Innovation

Amgen is committed to reimagining cardiometabolic treatment, utilizing insights from human biology to develop therapies that tackle the intertwined nature of cardiovascular and metabolic conditions effectively. Their focus on treatments like Repatha reflects not only Amgen's robust scientific framework but also a patient-centric vision that prioritizes survival and long-term health outcomes.

Fueled by over forty years of pioneering research, Amgen aims to redefine cardiometabolic care by addressing prevalent issues such as elevated LDL-C and cooccurring obesity. The company's potential breakthroughs, such as MariTide and olpasiran, are set to further revolutionize therapeutic strategies in this robust field, highlighting the dire need for a comprehensive and integrated approach to health management.

In conclusion, Amgen's presentation at the ADA 86th Scientific Sessions not only reinforced existing knowledge related to cardiovascular risk management in diabetes but also spotlighted the critical gaps in ongoing treatment strategies. With their deep commitment to innovation, Amgen continues to play a pivotal role in advancing care for patients dealing with these complex health challenges.